|
17 November 2004
Scottish Biomedical is delighted to be recognised as one of the top 20 fastest growing technology companies in Scotland, by the Deloitte Technology Fast 50 for 2004. Rankings are based on average percentage of sustained revenue growth over the five years from 1999 to 2004.
Scottish Biomedical's Business Development Director, Simon Bury credits this recognition to the company's customer focused approach and determination to satisfy customer needs at an individual level, "It is an honour for Scottish Biomedical to appear in the Deloitte Fast 50 for the first time, especially appearing within the top 20. We take a very customer orientated approach to the business and this, of course, is paying off in the long term."
Fred Hallsworth, head of technology at Deloitte in Scotland & Northern Ireland, said: "The Fast 50 programme has always been a reliable indicator of whether British innovation is leading to more growth and wealth creation. These companies have demonstrated how to survive and thrive in today's market by helping their customers reduce their costs and improve their performance, and our congratulations go to them on their significant achievements."
The Technology Fast 50 Programme seeks out those companies that have shown impressive growth rates in the telecommunications, hardware, software and biotechnology markets over the last three financial years. All companies considered for the award must be headquartered in the Scotland region, must be technology-intensive or use unique technology in problem solving, or must devote a high percentage of effort to research and development. Deloitte & Touche introduced the Special Awards in order to recognize those companies, which fall outside the criteria for Fast 50 qualification. www.fast50.co.uk
Scottish Biomedical is a privately owned, Glasgow-based, contract research company providing pre-clinical drug discovery services to pharmaceutical and biotech companies. With fully integrated biology and chemistry technology and expertise, the company is highly experienced in identifying new disease targets, developing primary and secondary assays, performing high throughput screening and identifying and optimising lead compounds. All of the intellectual property generated through Scottish Biomedical's drug discovery projects is owned by its clients. www.scottish-biomedical.com
For further information, please contact:
Neil McCahill
Marketing Manager
Scottish Biomedical
Tel:
Fax:
E-mail
Back to Latest News
|
